Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, declared on Wednesday that it has secured multiple contract awards with a combined estimated value exceeding GBP200,000, covering its Biometrics and Modelling & Simulation service lines.

These awards include extensions to existing clinical development projects with two clinical-stage biotechnology companies focused on immunology and infectious disease, as well as a new Modelling & Simulation contract with a Boston-based biotechnology company developing cancer immunotherapies.

The projects will leverage Physiomics' expertise in biostatistics, modelling, simulation and data science to support drug development activities including data analysis, programme development and model-informed development. The company said the contracts demonstrate continued growth of its diversified service offering and expanding client relationships.